Revolution Medicines’ pancreatic cancer drug doubles survival time in Phase 3news2026-04-13T12:00:21+00:00April 13th, 2026|Endpoints News|
Plan for remade ACIP panel adds focus on vaccine safety, matching Kennedy’s pushnews2026-04-10T19:00:33+00:00April 10th, 2026|Endpoints News|
Bayer pharma executive predicts US-Europe price spreads will narrownews2026-04-10T18:28:15+00:00April 10th, 2026|Endpoints News|
FDA rejects Replimune cancer therapy, saying company didn’t resolve trial doubtsnews2026-04-10T16:16:03+00:00April 10th, 2026|Endpoints News|
FDA plans another safety study of abortion drug after court ordernews2026-04-09T18:29:48+00:00April 9th, 2026|Endpoints News|
AbbVie suggests new interpretation of ‘patient’ is necessary in 340B lawsuitnews2026-04-09T18:18:32+00:00April 9th, 2026|Endpoints News|
Roche dips into DACs with existing partner C4 Therapeutics for $20M upfrontnews2026-04-09T14:17:59+00:00April 9th, 2026|Endpoints News|
PhRMA head Steve Ubl to step down at end of yearnews2026-04-08T16:15:29+00:00April 8th, 2026|Endpoints News|
Insmed shelves Brinsupri in skin disease after mid-stage flopnews2026-04-08T10:06:51+00:00April 8th, 2026|Endpoints News|
Did Eli Lilly just strike another gold mine?news2026-04-07T19:29:41+00:00April 7th, 2026|Endpoints News|
